LinkedIn · Mar 2026
Serinus added Daniel Nomura to its Scientific Advisory Board to help advance the ApoXY platform and therapeutic pipeline in molecular glues and targeted protein degradation.
Combinations therapy by rational design
Company research
Public company, workplace, funding, and market signals
Overview
Serinus Biosciences is a New York-based biotechnology company developing AI-driven protein-interaction drug discovery and combination-therapy technologies for oncology and immunology. Its public materials emphasize interactome foundation models, the ApoXY platform, and a Pep-to-Mol workflow to find druggable vulnerabilities in tumor resistance.
Primary product
ApoXY platform for protein-interaction drug discovery and molecular-glue therapeutics
Founded
2022
Headquarters
New York, New York, United States
Team size
1-10
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
AI drug discovery / oncology therapeutics
Offices
430 E 29th St, New York, NY 10016
New York City, NY (Manhattan office)
Business model
co-development partnerships
drug discovery services
Funding
Stage
early-stage VC
Total raised
$5.9M
Latest round
Venture Round · Nov 2024
Latest amount
$1.6M
People & investors
Leadership
Co-Founder & CEO
Co-Founder & CTO
Senior Director, Head of Biology
Work & culture
Small, tight-knit, mission-driven team with a fast-growth, high-ownership culture that prefers in-person collaboration in New York City.
Work style
Onsite
Compensation
A public job posting for an Associate Computational Scientist listed $75K-$95K base salary plus an above-market equity package.
Benefits
100% premium health insurance coverage
100% dental insurance coverage
100% vision insurance coverage
FSA
commuter benefits
unlimited PTO
10 federal holidays
on-site gym
above-market equity package
Product & market
Pricing
B2B co-development partnerships and service-based discovery collaborations
Differentiators
- —Interactome foundation models focused on protein interactions
- —ApoXY platform for massively multiplexed, AI-integrated cellular screening
- —Emphasis on overcoming tumor resistance with combination therapies
- —Uses cancer-specific proteomic maps plus drug response data to prioritize combinations
- —Built around protein-complex-centric innovation and clinical translation
Technology
Python
Bash
Illumina
QuickBooks
Microsoft
AWS
GCP
Azure
Customers
pharma and biotech co-development partners
Competitors
Angiocrine Bioscience
Precision Biologics
Mill Creek Life Sciences
Scale & contact
Latest news
LinkedIn · Jun 2025
The company announced participation in ARPA-H ADAPT, a $142M initiative to track tumor changes and develop adaptive combination treatments, alongside UC San Diego and other academic partners.
LinkedIn · Oct 2024
Adam Yaari said Serinus was selected as one of two companies to present at the NewYorkBIO Annual Holiday Reception at the New York Stock Exchange.
LinkedIn · Nov 2023
Serinus announced acceptance into MDSS and Endless Frontier Labs, two programs intended to accelerate company growth.
LinkedIn · May 2023
The company announced Lee McDaniel as Director of Bioinformatics, highlighting his background in computational cancer genomics and translational research.
Jobs and careers at Serinus Biosciences
0 jobs at Serinus Biosciences
No open positions
Check back later for new openings